儿童医院获得性静脉血栓栓塞（HA-VTE）已受到广泛关注。我们旨在分析住院儿童中HA-VTE的比例和危险因素。我们对1990年至2023年的4个数据库进行了全面的系统检索。 Cochran Q检验用于评估研究效应大小的异质性，I2统计量用于量化异质性。当异质性较低 (I2 < 25%) 或较高 (I2 > 25%) 时，分别通过固定效应模型或随机效应模型中的反方差加权方法计算汇总估计值。总共 105 篇原始论文研究纳入20,718,294名患者，儿童HA-VTE比例为4.1%（95% CI，2.9%-5.2%）。尽管静脉血栓栓塞的比例在不同研究期间有所增加，但差异无统计学意义。在基于国家的亚组分析中，儿童HA-VTE的比例在英国最低，在西班牙最高；而在基于地区的亚组分析中，该比例在亚洲最低，在北美最高。确定了多种HA-VTE危险因素，包括中心静脉导管的使用、年龄>10岁、手术、损伤、感染、肥胖、机械通气、输血、恶性肿瘤、凝血和出血性疾病以及住院时间。研究中，我们系统分析了住院儿童HA-VTE的比例及危险因素。我们的研究结果为儿科患者 HA-VTE 的预防和治疗提供了宝贵的见解。© 2024 作者。

Hospital-acquired venous thromboembolism (HA-VTE) in children has been widely regarded.We aimed to analyze the proportion and risk factors for HA-VTE in hospitalized children.We conducted a comprehensive systematic search across 4 databases from 1990 to 2023. Cochran Q test was used to evaluate the heterogeneity of the effect sizes of study, and I2 statistic was used to quantify the heterogeneity. Pooled estimates were calculated by the inverse-variance weighted method in a fixed-effect model or a random-effect model when heterogeneity was low (I2 < 25%) or high (I2 > 25%), respectively.In total, 105 original papers and 20,718,294 patients were included in the study, and the proportion of HA-VTE in children was 4.1% (95% CI, 2.9%-5.2%). Although the proportion of venous thromboembolism increased over the various research periods, the differences were not statistically significant. In the subgroup analysis based on country, the proportion of pediatric HA-VTE was lowest in the United Kingdom and highest in Spain, whereas when based on region, the proportion was lowest in Asia and highest in North America. Multiple HA-VTE risk factors were identified, including central venous catheter use, age of >10 years, surgery, injury, infection, obesity, mechanical ventilation, blood transfusion, malignancy, coagulation and hemorrhagic disorders, and length of hospital stay.In this study, we systematically analyzed the proportion and risk factors of HA-VTE in hospitalized children. Our findings provide valuable insights for the prevention and treatment of HA-VTE in pediatric patients.© 2024 The Author(s).